Hematologic Malignancy Clinical Trial
Official title:
The Effect of a Smartphone Application for Encouraging Physical Activity on the Amount of Activity Performed by Patients With Diabetes or Hematological Malignancies
A smartphone app will be installed on smartphones of patients with type 2 diabetes or hematologic malignancies that do not exercise. The app will send SMS messages to encourage exercise. The exercise will be quantified by the smartphone accelerometer and clinical data, including HbA1c will be collected.
The aim of the study is to increase patients' physical activities by using a dedicated
cellular application that will encourage patients to adhere to their doctor recommendation
on a personal basis.
Primary outcome In diabetic patients: measuring an increase in daily physical activity In
cancer patients: improvement of quality of life in correlation with the level of physical
activity
Secondary outcomes In diabetic patients: improved glycemic control as assessed by sequential
blood tests for HbA1c.
The patients will fill quality of life questionnaires (SF36) at recruitment and after 6
months. After 6 months the patients will also fill a questionnaire about their experience of
using the app.
Each recruited patient will have an Android based smart phone. Each patient will provide:
1. Approval to join the experiment
2. Age, gender, height
3. Telephone number (for SMS)
Length of intervention - at least 6 months per patient. Each patient will be randomly
assigned into one of two groups, which will specify feedback relative to himself or to
others or a weekly reminder to exercise.
Number of patients:
1. Diabetes: 150 patients, of which 50 are controls.
2. Cancer: 100 patients, of which 20 are controls. All patients will receive instruction
about the importance of physical activity and a personal recommendation for activity
level, n sessions of activity per week, and time span per session (i.e., at least 2
hours of walking per week divided to 3 walking sessions per week) Patients in the
treatment arms will receive at least n (number of commended sessions) messages per week
of positive feedback if activity performed or negative feedback if not performed. At
the chosen day each week the patient will receive a summary of the exercise for all the
week.
Feedback Possible feedback
(NOTE - these the the actual feedback messages that the participants will receive, and are
therefore in the second person):
1. Negative feedback: "You need to exercise to reach your activity goals. Please remember
to exercise tomorrow".
2. Positive feedback:
1. Relative to self: "You're exercise level is higher than last week. Keep up the
good work"
2. Relative to others: "You're exercising more than the average person. Keep up the
good work"
3. Control arm: "Did you remember to exercise?"
Technical requirements
1. App - will collect physical activity and send it to a server. App will run in
background without need to restart on reboot.
2. Server - Collects physical activity
Feedback policies The experiment will have two phases of feedback. Phase 1
The investigators begin with no data, so the policy at this stage is as follows:
1. Positive feedback will be sent each day if user has surpassed 1/7th of weekly activity
that day.
2. Negative feedback will be sent every 3 days, if activity hasn't passed 1/7th of
activity.
Each day, with a probability of 0.2, a random decision on feedback will be made.
This phase will last approximately 4 weeks. Phase 2 Using a learning algorithm (see below)
the computer will adjust the feedback, and decide daily on the feedback (positive \ negative
\ none).
Policy learning The investigators will start with a simple policy learning strategy, and
later use more sophisticated methods that will have a state-space representation of the
user.
The initial algorithm will represent each user at each day using the following attributes:
1. Demographics (age and gender)
2. Expected versus actual activity level this week (ratio of the two)
3. Last feedback given (positive \ negative)
4. Day of the week (we will use week-long cycles). The goal of the algorithm is to give
feedback today so as to encourage activity tomorrow.
When training the algorithm, the computer will have a feature vector comprising of the
attributes above, and a matrix of actions (for day t). The output to be predicted is whether
the activity level on the following day (t+1).
There can be two types of feedback depending on weekly and daily behaviors:
Weekly goal Not achieved Achieved Daily goal (on day (t+1)) Not achieved 1 1+alpha Achieved
1+alpha 1 (alpha>0) The algorithm will pay a higher penalty if, for example, on a given day
the message encouraged activity, but the weekly goal was not achieved compared to if it was.
For simplicity, the initial learning algorithm will be linear, until enough data is
collected. That is, given a matrix:
X = (demographics, expected vs. actual activity, last feedback, day of the week, actions)
And a vector showing the amount of activity on the following day, weighted as in the table
above, denoted by Y, we will learn a vector of weights w such that: X * w = Y.
In phase 2 of the project the computer will use other learning algorithms. Exploration
(random action at a given day) will continue throughout both phases at the same level.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04889937 -
Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population
|
||
Not yet recruiting |
NCT05820126 -
Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial
|
Phase 2 | |
Active, not recruiting |
NCT04509765 -
A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT
|
N/A | |
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Withdrawn |
NCT03986086 -
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT02512666 -
Non Invasive Optical Imaging of WBC Count
|
N/A | |
Withdrawn |
NCT02207764 -
Reiki as a Complementary Therapy: A Pilot Study
|
N/A | |
Not yet recruiting |
NCT02193399 -
Physiotherapy in Hematopoietic Stem Cell Transplantation
|
N/A | |
Terminated |
NCT01846429 -
Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain
|
Phase 1 | |
Terminated |
NCT01215981 -
Influenza Vaccine Post Allogeneic Transplant
|
N/A | |
Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT04392128 -
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
|
Phase 2 | |
Recruiting |
NCT06102213 -
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT04552288 -
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
|
Phase 2 | |
Completed |
NCT03654404 -
A Proof-of-Concept Trial of a Positive Psychology Intervention for Allogeneic Stem Cell Transplant Patients
|
N/A | |
Recruiting |
NCT05384288 -
Response to Influenza Vaccination in Pediatric Oncology Patients
|
||
Recruiting |
NCT05084027 -
Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT
|
Phase 2 |